NZ505648A - Hexadecylphosphocholine (HPC) and a flow controlling agent and/or a lubricant and a filler in a daily dosage of 10-250 mg - Google Patents

Hexadecylphosphocholine (HPC) and a flow controlling agent and/or a lubricant and a filler in a daily dosage of 10-250 mg

Info

Publication number
NZ505648A
NZ505648A NZ505648A NZ50564898A NZ505648A NZ 505648 A NZ505648 A NZ 505648A NZ 505648 A NZ505648 A NZ 505648A NZ 50564898 A NZ50564898 A NZ 50564898A NZ 505648 A NZ505648 A NZ 505648A
Authority
NZ
New Zealand
Prior art keywords
hexadecylphosphocholine
hpc
lubricant
filler
daily dosage
Prior art date
Application number
NZ505648A
Other languages
English (en)
Inventor
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Jurgen Engel
Werner Sarlikiotis
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Priority to NZ505648A priority Critical patent/NZ505648A/xx
Publication of NZ505648A publication Critical patent/NZ505648A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ505648A 1998-01-22 1998-01-22 Hexadecylphosphocholine (HPC) and a flow controlling agent and/or a lubricant and a filler in a daily dosage of 10-250 mg NZ505648A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ505648A NZ505648A (en) 1998-01-22 1998-01-22 Hexadecylphosphocholine (HPC) and a flow controlling agent and/or a lubricant and a filler in a daily dosage of 10-250 mg

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ505648A NZ505648A (en) 1998-01-22 1998-01-22 Hexadecylphosphocholine (HPC) and a flow controlling agent and/or a lubricant and a filler in a daily dosage of 10-250 mg
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
NZ505648A true NZ505648A (en) 2002-10-25

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ505648A NZ505648A (en) 1998-01-22 1998-01-22 Hexadecylphosphocholine (HPC) and a flow controlling agent and/or a lubricant and a filler in a daily dosage of 10-250 mg

Country Status (24)

Country Link
US (1) US6544551B1 (enExample)
EP (1) EP1051159B1 (enExample)
JP (1) JP2002501015A (enExample)
KR (1) KR100517399B1 (enExample)
CN (1) CN100413492C (enExample)
AT (1) ATE215817T1 (enExample)
AU (1) AU756805B2 (enExample)
BR (1) BR9814772A (enExample)
CA (1) CA2318260C (enExample)
CZ (1) CZ299229B6 (enExample)
DE (1) DE69804865T2 (enExample)
DK (1) DK1051159T3 (enExample)
ES (1) ES2175663T3 (enExample)
HU (1) HUP0004363A3 (enExample)
IL (1) IL136196A (enExample)
NO (1) NO20003674L (enExample)
NZ (1) NZ505648A (enExample)
PL (1) PL189654B1 (enExample)
PT (1) PT1051159E (enExample)
SI (1) SI1051159T1 (enExample)
SK (1) SK284839B6 (enExample)
TR (1) TR200001717T2 (enExample)
UA (1) UA68372C2 (enExample)
WO (1) WO1999037289A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
AU2002346284A1 (en) * 2002-04-26 2003-11-10 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
NZ538428A (en) 2002-07-30 2006-09-29 Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor medicaments
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
ES2525497T3 (es) 2004-10-08 2015-10-09 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
PT2642981T (pt) 2010-11-22 2017-06-16 Oblita Therapeutics Bvba Resumo
EP3616701A1 (en) 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
JP2016515602A (ja) * 2013-04-08 2016-05-30 アカデミッシュ メディッシュ セントラム Ｉｂｄの治療に使用するためのミルテホシンまたはペリホシン
JP6566450B2 (ja) 2014-09-17 2019-08-28 ステアライフ・インディア・プライベート・リミテッド 発泡組成物及びそれを製造する方法
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
PL3965739T3 (pl) 2019-04-12 2025-01-13 Oblita Therapeutics Bvba Postacie dawkowane będące tabletkami oleilofosfocholiny

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59778B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicament with anti-tumour action containing hexadecylphosphocholine
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0419998A3 (en) * 1989-09-27 1991-10-23 Asta Pharma Aktiengesellschaft Use of alkylphosphonic acid derivatives for the treatment of psoriasis
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
TR200001717T2 (tr) 2000-11-21
CA2318260C (en) 2006-11-21
HUP0004363A3 (en) 2002-12-28
AU6212198A (en) 1999-08-09
SI1051159T1 (en) 2002-10-31
DE69804865T2 (de) 2002-11-07
EP1051159B1 (en) 2002-04-10
CN1283111A (zh) 2001-02-07
CZ20002596A3 (cs) 2000-10-11
SK9862000A3 (en) 2000-11-07
KR20010034311A (ko) 2001-04-25
PT1051159E (pt) 2002-09-30
CN100413492C (zh) 2008-08-27
DK1051159T3 (da) 2002-08-05
PL189654B1 (pl) 2005-09-30
ES2175663T3 (es) 2002-11-16
IL136196A (en) 2004-07-25
ATE215817T1 (de) 2002-04-15
NO20003674D0 (no) 2000-07-18
BR9814772A (pt) 2000-10-24
EP1051159A1 (en) 2000-11-15
CA2318260A1 (en) 1999-07-29
CZ299229B6 (cs) 2008-05-21
IL136196A0 (en) 2001-05-20
HUP0004363A2 (hu) 2001-04-28
NO20003674L (no) 2000-07-18
SK284839B6 (sk) 2005-12-01
DE69804865D1 (de) 2002-05-16
KR100517399B1 (ko) 2005-09-28
UA68372C2 (en) 2004-08-16
PL342838A1 (en) 2001-07-16
JP2002501015A (ja) 2002-01-15
WO1999037289A1 (en) 1999-07-29
US6544551B1 (en) 2003-04-08
AU756805B2 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
NZ505648A (en) Hexadecylphosphocholine (HPC) and a flow controlling agent and/or a lubricant and a filler in a daily dosage of 10-250 mg
MXPA01004547A (es) Administracion oral de analogos de adenosina.
BR9914251A (pt) Formulações orais de liberação sustentada
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
IL123636A0 (en) Bioadhesive solid dosage form
BG104727A (en) Pharmaceutical composition of topiramate
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
EP1025845A3 (en) Hydromorphone tablets
PL334566A1 (en) Treatment of sclerosis multiplex by oral and inhalatory administration of a copolymer-1
SG65584A1 (en) Methods for inhibiting bone loss with 3, 4-diarylchroman
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
IL139320A0 (en) Pharmaceutical compositions containing human parathyroid hormone
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
FR2500303B1 (enExample)
MY114282A (en) Anthracycline derivatives
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
YU13599A (sh) Primena farmaceutske kompozicije za dobijanje leka u obliku gela
MX9709838A (es) Composiciones farmaceuticas estables que contienen hidratos de tiludronato y proceso para producir las composiciones farmaceuticas.
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
AU665397B2 (en) Fungicidal compositions
MY138319A (en) 1,5-benzodiazepine derivatives
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ZENTARIS AG, DE

Free format text: OLD OWNER(S): ASTA MEDICA AG

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)